* Information on the genetic variation of plant response to elevated CO(2) (e[CO(2)]) is needed to understand plant adaptation and to pinpoint likely evolutionary response to future high atmospheric CO(2) concentrations. * Here, quantitative trait loci (QTL) for above- and below-ground tree growth were determined in a pedigree - an F(2) hybrid of poplar (Populus trichocarpa and Populus deltoides), following season-long exposure to either current day ambient CO(2) (a[CO(2)]) or e[CO(2)] at 600 microl l(-1), and genotype by environment interactions investigated. * In the F(2) generation, both above- and below-ground growth showed a significant increase in e[CO(2)]. Three areas of the genome on linkage groups I, IX and XII were identified as important in determining above-ground growth response to e[CO(2)], while an additional three areas of the genome on linkage groups IV, XVI and XIX appeared important in determining root growth response to e[CO(2)]. * These results quantify and identify genetic variation in response to e[CO(2)] and provide an insight into genomic response to the changing environment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1469-8137.2007.02091.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anaerobic probiotics-in situ Se nanoradiosensitizers selectively anchor to tumor with immuno-regulations for robust cancer radio-immunotherapy.
Biomaterials
January 2025
Department of Pharmacy of Puning People's Hospital (Guangdong Postdoctoral Innovation Practice Base of Jinan University), Department of Chemistry, State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangdong, 510632, China. Electronic address:
Developing translational nanoradiosensitizers with multiple activities in sensitizing tumor cells and re-shaping tumor immunosuppressive microenvironments are urgently desired for addressing the poor therapeutic efficacy of radiotherapy in clinic. Inspired by the anaerobic and immunoagonist properties of the probiotic (bifidobacterium longum, BL), herein, a biomimetic Selenium nanoradiosensitizer in situ-formed on the surface of the probiotic (BL@SeNPs) is developed in a facile method to potentiate radiotherapy. BL@SeNPs selectively target to hypoxia regions of tumors and then anchor on the surface of tumor cells to inhibit its proliferation.
View Article and Find Full Text PDFHow therapist effects shape pain-related outcome improvement in psychological treatments for chronic pain.
Curr Opin Psychol
January 2025
Department of Rehabilitation Medicine, The University of Washington, Seattle, WA, USA.
Psychological chronic pain treatments have variable efficacy across individual patients, and on average tend to produce modest effects. In order to improve treatment outcomes, the past decade has seen a rapid increase in research focused on determining the mechanisms underlying treatment-related gains. The near exclusive focus of this research has been on uncovering patient-related mediators and moderators.
View Article and Find Full Text PDFConceptualizing a load and volume autoregulation integrated velocity model to minimize neuromuscular fatigue and maximize neuromuscular adaptations in resistance training.
Eur J Appl Physiol
January 2025
College of Kinesiology, University of Saskatchewan, Saskatoon, SK, Canada.
Resistance training (RT) load and volume are considered crucial variables to appropriately prescribe and manage for eliciting the targeted acute responses (i.e., minimizing neuromuscular fatigue) and chronic adaptations (i.
View Article and Find Full Text PDFImmunonutrition to improve the quality of life of upper gastrointestinal cancer patients undergoing neoadjuvant treatment prior to surgery (NEOIMMUNE): double-blind randomized controlled multicenter clinical trial.
Dis Esophagus
January 2025
Department of Digestive and Oncological Surgery, Claude Huriez Hospital, Chu Lille, Lille, France.
Background: Malnutrition is common with esophagogastric cancers and is associated with negative outcomes. We aimed to evaluate if immunonutrition during neoadjuvant treatment improves patient's health-related quality of life (HRQOL) and reduces postoperative morbidity and toxicities during neoadjuvant treatment.
Methods: A multicenter double-blind randomized controlled trial (RCT) was undertaken.
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Nat Med
January 2025
Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), University of Vic - Central University of Catalonia, Barcelona, Spain.
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!